ACM
MBX

ACT Capital Management’s MBX Biosciences MBX Stock Holding History

ACT Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$442K Sell
8,000
-1,000
-11% -$34.9K 0.29% 40
2026
Q1 		$269K Buy
+9,000
New +$306K 0.21% 41

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

ACT Capital Management's MBX Position: Q2 2026 in Review

ACT Capital Management reduced its MBX Biosciences (MBX) stake by 11% in Q2 2026, selling an estimated $34.9K and leaving 8,000 shares worth $442K. The position accounts for 0.29% of the portfolio, ranked #40.

ACT Capital Management first reported a position in MBX in Q1 2026 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • ACT Capital Management held 8,000 shares of MBX Biosciences worth $442K as of Q2 2026.
  • ACT Capital Management sold 1,000 MBX Biosciences shares in Q2 2026, an estimated $34.9K.
  • MBX Biosciences made up 0.29% of ACT Capital Management's portfolio in Q2 2026, its #40 holding.
  • ACT Capital Management first reported a position in MBX Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.